idea-015 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the user. Here that is two people who have to be convinced separately — the woman with symptomatic stage II-III anterior or apical prolapse who has elected non-surgical management and has to wear the device, and the gynecologist, urogynecologist or women's-health NP who has to change how a fitting visit runs.
How to read this: every slide is a condition, not a conclusion. a bracketed claim reference points at the numbered claim of knowledge-base/candidates/idea-015.md whose position it names, with the tag that claim carries there right now, copied and never adjusted; [no claim] means nothing in the file speaks to this. No number appears here that is not in a claim. See docs/deck-spec.md.
First build, at stage: verified. Seven of this file's claims are verified and all seven are regulatory-register, patent-register or CMS-payment facts. Not one of them is about a user. The rubric scores no factor for whether anyone wants this, so this deck is mostly conditions — that is the expected shape, and it is information about the pipeline as much as about the idea.
Would have to be true: A woman with symptomatic stage II-III anterior-compartment or apical prolapse who has elected non-surgical management would have to be sitting in a fitting visit today that runs as a trial-and-error progression through discrete stocked sizes, with a material minority leaving without a usable fit.
Where it stands: The volume of that moment is the best-evidenced thing on this deck: 73,363 CPT 57160 fitting-and-insertion services nationally, of which 66,773 (about 91%) are office or other non-facility [claim 10: verified] — and the file is explicit that this is Medicare fee-for-service only and therefore a floor on US volume, never a market size. The disease behind it is sized at approximately 2.9% symptomatic pelvic organ prolapse among US women from Nygaard 2008 (PMID 18799443), whose content was re-retrieved and matches exactly but which is held at [claim 13: unconfirmed] on structural grounds, and which sizes the disease rather than the billable device population. The failure half of the moment — the claimed 56-80% initial fitting success and the trial-and-error size ladder itself — is [claim 14: unconfirmed], and the file records that a literature sweep did not produce the 56-80% range from a primary source and that the ladder half cites no source at all. The nearest registry evidence that a size ladder is real is indirect: K153422, a cleared "Panpac Disposable Pessary Fitting Set" (noted under claim 5), and the ring / ring-with-support / ring-with-knob / Marland / Gellhorn / cube line covered by K231786 [claim 26: verified].
What would settle it: A named, retrieved paper reporting an overall initial pessary-fitting success rate in a general POP population — the file's own note rules out PMID 32649024, which reports predictors of unsuccessful fitting and states no overall rate. The Scores table names this as cheap PubMed work for the Mechanism factor.
If it's false: If initial fitting failure is rare, the problem this device solves is not the problem clinicians have, and Factor 6 (Mechanism & clinical risk) loses the half of its score that claims 14 and 15 carry. Slides 2, 5 and 6 become moot together.
Would have to be true: The patient would have to change nothing — insertion, removal, cleaning and wear are those of a conventional ring pessary — while the fitting clinician would have to abandon withdraw-and-try-the-next-size and instead set, lock and if necessary re-set one device's diameter within a single visit, then write the set diameter into the chart so it can be reproduced at follow-up.
Where it stands: The behaviour change is unmeasured and now on record rather than implied: clinicians adopting an in-visit adjust-and-lock procedure and charting the set diameter is [claim 27: unverified]. The adjacent purchasing question — clinicians preferring to stock a single adjustable SKU over a multi-size fitting set, and non-fitting practices starting to fit once inventory burden falls — is [claim 22: unconfirmed], and the file records that the adoption connector returned unverifiable, with an explicit instruction that a model-generated stakeholder opinion here would be a fabricated claim. Whether the adjustment can physically be performed in situ rather than by withdrawing the device — which decides whether this is a workflow change at all — is the feasibility deck's Slide 4 and is [claim 36: unverified].
What would settle it: Structured interviews or a preference survey with US pessary-fitting clinicians (urogynecology, general gynecology, women's-health NPs), attached by a human. No connector in this repo reaches clinician purchasing or practice-line behaviour; the file says so in claim 22's own note.
If it's false: If clinicians will not re-adjust in visit and simply reach for a second device, the single-SKU inventory argument survives but the fitting-success argument does not — and the fitting-success argument is what claims 23 and 27 together carry.
Would have to be true: Four parties beyond the patient would have to say yes: the fitting clinician, the practice that buys the SKU, a DMEPOS supplier able to bill the device, and the payer whose coverage policy the dispense sits under.
Where it stands: The channel is an inference the file flags as decisive rather than a finding: that the device is billed to a DME MAC under A4561/A4562 while CPT 57160 is billed separately to the Part B MAC — so a DMEPOS supplier channel stands between the manufacturer and revenue — is [claim 7: unconfirmed], with the PFS half confirmed via [claim 8: verified] and the device half blocked on missing CMS files and on a claims-processing-manual fact no connector here reaches. That A4561 and A4562 are active DMEPOS codes at all is [claim 6: unconfirmed], unconfirmed for a missing-file reason rather than because CMS is silent. Whether any DME MAC coverage policy would accept this dispense is [claim 31: unverified]. The practice's purchasing yes is [claim 22: unconfirmed]. The full money-side treatment of this chain is the viability deck's Slides 1 and 2; it is referenced here rather than restated.
What would settle it: Fetching data/hcpcs_level_ii.csv and data/hcpcs_payment_rates.csv (the exact CMS releases named in claims 6 and 11) closes the code question; a DME MAC LCD/policy-article search for pessary coverage criteria closes the coverage question. The contractor-routing question needs a human read of the Medicare claims-processing manual — this repo has no typed connector for it.
If it's false: If the device cannot be dispensed through a channel a practice already uses, the clinician's yes does not convert into a fitted patient, and Factor 2 (Reimbursement) loses the pathway half it was scored on — the Scores table already grades it "codes plausibly exist," not "pathway exists."
Would have to be true: The woman would have to give up no more than she gives up today: the same cost share on the same two codes, the same at-home cleaning routine, the same follow-up cadence — and she would have to be willing to wear a device with a mechanical joint inside her for months at a time.
Where it stands: No claim in this file carries a patient cost-share figure of any kind. The two payment amounts that exist are payments to providers, not patient costs: 57160 pays a national unadjusted non-facility $70.48 at conversion factor 33.4009 [claim 8: verified], and the device allowed amount of roughly $69-$89 rests on a vendor blog page, not the CMS file [claim 11: unconfirmed]. That the patient's out-of-pocket is no worse than for a conventional pessary is now on record as [claim 29: unverified]. The acceptability of a mechanical joint worn intravaginally is [claim 28: unverified] — and it runs against the direction of the two most recent cleared entrants in this code, both of which went the other way: K190277 ProVate is a single-use collapsible device [claim 3: verified], and the patient-specific competitor is bespoke-manufactured rather than mechanised [claim 20: unconfirmed]. The at-home cleaning routine being unchanged is [claim 37: unverified]. The recurring-visit cost is real but asymmetric: removal, cleaning and reinsertion being bundled into the E/M service rather than separately reportable is [claim 9: unconfirmed] and, per the file, permanently unconfirmed through this repo for an AMA-licensing reason — which matters because that bundling is the chair-time story the whole adoption thesis rests on.
What would settle it: For cost share, the CMS DMEPOS fee-schedule file plus the standard Part B beneficiary coinsurance rule, read by a human — no connector here returns a patient liability. For acceptability and cleaning, a patient-preference study and a usability study on a physical prototype; neither exists for an unbuilt device.
If it's false: If a jointed reusable device is less acceptable than a solid one, the discontinuation curve this idea is built to bend [claim 15: unconfirmed] bends the wrong way, and the central clinical bet in [claim 23: unconfirmed] is lost on tolerability rather than on fit.
Would have to be true: A fitting clinician would have to see, in a population like her own, that in-visit re-adjustment produces a retained, tolerated fit more often than reaching for the next discrete size — not that the device is cleared, and not that it is cheaper to stock.
Where it stands: That comparison is the central clinical bet and is [claim 23: unconfirmed], recorded as unverifiable by construction because no comparative data can exist for a device that does not yet exist. The nearest read available is a competitor's: patient-specific 3D-printed pessaries in patients who had already failed standard pessaries achieved 77.0% initial fitting success (95% CI 68.5-83.7) and 63.7% continued use at final follow-up across 113 patients at 18 Canadian sites [claim 20: unconfirmed] — directionally supportive of the premise that refitting rescues failures, but a different intervention (bespoke manufacture, not in-visit mechanical adjustment), single-arm, and in a selected population. The baseline it would have to beat is itself unsettled: the file records that the source behind [claim 15: unconfirmed] reports 20-60% discontinuation at 24 months, not the 30-50% at 12 months the claim states, and that the study excluded women who failed initial fitting.
What would settle it: A prospective comparative fitting study against conventional size-ladder fitting, which the Factor 6 row already names. Nothing short of that is evidence; everything short of it is a lead.
If it's false: If re-adjustment does not beat the next discrete size, the device is a single-SKU inventory convenience with no clinical argument, and Factor 6 falls to the plausibility of mechanical support alone — which every incumbent pessary already has.
Would have to be true: In a first handful of real fittings, a clinician would have to achieve a comfortable, retained fit in one visit for a patient who had failed the first diameter tried — and a second visit still being needed, or the set diameter drifting between visits, would falsify it.
Where it stands: Nothing in the file is an observation of this device in use; it does not exist yet. Three things bound the test rather than answer it: about 91% of Medicare fittings are office-based [claim 10: verified], so the setting to recruit in is the ordinary gynecology office; the retention endpoint a competitor's regulated study used is retention under Valsalva against the subject's own current pessary in women who are current ring or Gellhorn users in sizes 1.5"-3.5" [claim 21: unconfirmed], which is a ready-made protocol shape; and [claim 27: unverified] plus [claim 36: unverified] are exactly what such a session would observe.
What would settle it: A handful of supervised fittings on a physical prototype in one urogynecology clinic, with the set diameter recorded and re-measured at a follow-up visit — a human act. Before any patient is involved, the bench conditions on the feasibility deck's Slide 5 have to hold first; this slide is downstream of that one, not parallel to it.
If it's false: If a first cohort still needs a second visit, the workflow saving is notional and both [claim 22: unconfirmed] and [claim 27: unverified] lose the argument that was meant to carry them.
Every condition above with nothing verified behind it. Read this slide first. The verified claims cited on this deck (8, 10, 3, 26) establish a payment amount, a service volume, and what other people's devices were cleared to do — none of them establishes that anyone wants this one.
Fifteen conditions, none of them verified. The honest reading is not the length of this list but its composition: four of these are unverified only because this deck just put them on record, and three more (claims 9, 22, 23) are marked in the file as permanently unclosable by any agent in this repo.
If only one thing from this chair could be checked: whether a fitting clinician will actually re-adjust in the visit instead of reaching for the next device — [claim 27: unverified], with [claim 22: unconfirmed] behind it.
Why this one rather than the others. The patient-side conditions are mostly permissive: she already wears a silicone ring, already cleans it at home, already comes back for maintenance, and the file's own mechanism description says her routine is unchanged. The clinician-side condition is constitutive — every other benefit this candidate claims (one SKU instead of a fitting set, fewer failed fittings, a diameter recorded and reproduced at follow-up) exists only if the fitting visit runs differently. And unlike the clinical bet in claim 23, which needs a prospective comparative study and a built device, this one can be tested with twenty interviews and a prototype nobody has to wear.
Naming it is not a recommendation, a gate, or a kill. It is the answer to "check what first."